Semaglutide
Regulate appetite and support metabolic health.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. It slows gastric emptying, promotes satiety signaling in the hypothalamus, and improves insulin sensitivity. Originally developed for type 2 diabetes research, it has become one of the most studied peptides for metabolic health and body composition.
Key Benefits
- Reduces appetite through central satiety signaling
- Improves insulin sensitivity
- Supports cardiovascular metabolic markers
- Slows gastric emptying for sustained fullness
Set a goal (top of the page) to see how Semaglutide scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Constipation
- Decreased appetite
- Risk of thyroid C-cell tumors (boxed warning)
- Pancreatitis (uncommon)
Legal & Regulatory Status
Prescription required. FDA-approved: Ozempic/Rybelsus (type 2 diabetes) and Wegovy (chronic weight management). Carries a boxed warning for thyroid C-cell tumors.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- FDA prescribing information — Wegovy/Ozempic (semaglutide), via DailyMed
- STEP phase-3 obesity trials program overview (PMID 32441473)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
